



HAMILTON, BROOK, SMITH & REYNOLDS, P.C.

JFW

REVOCATION OF POWER OF ATTORNEY WITH NEW POWER OF ATTORNEY and CHANGE OF CORRESPONDENCE ADDRESS	Application/Patent Number	10/519,594
	Filing/Issue Date	December 28, 2004
	First Named Inventor/Patentee	David Cavalla
	Confirmation Number	2624
	Group Art Unit	1617
	Examiner Name	Layla Soroush
	Attorney Docket Number	3506.1021-000
Title	4-(2-Fluorophenyl)-6-Methyl-2(1-Piperazinyl)Thieno[2,3-D] Pyrimidine in the Treatment of Functional Bowel Disorder	
I hereby revoke all previous powers of attorney given in the above-identified application.		
<input type="checkbox"/> I hereby appoint the following practitioner(s): [Not to exceed 10] OR <input checked="" type="checkbox"/> I hereby appoint the practitioners associated with the Customer Number: 021005		
Please change the correspondence address for the above-identified application to: <input checked="" type="checkbox"/> Customer Number 021005 Hamilton, Brook, Smith & Reynolds, P.C. 530 Virginia Road P.O. Box 9133 Concord, Massachusetts 01742-9133 <input type="checkbox"/> Other		
Please direct all telephone calls and facsimiles to: Name <u>Susan M. Abelleira, Esq.</u> Tel. No. <u>978-341-0036</u> Fax No. <u>978-341-0136</u>		
I am the: <input type="checkbox"/> Applicant/Inventor. <input checked="" type="checkbox"/> Authorized representative of the Assignee, Dynogen Pharmaceuticals, Inc., of the entire interest. See 37 CFR § 3.71. A Statement under 37 CFR § 3.73(b) is enclosed. <input type="checkbox"/> Authorized representative of the Assignee, [FILL IN WITH NAME OF ASSIGNEE], together with [FILL IN WITH NAME OF ASSIGNEE], of the entire interest. A Statement under 37 CFR § 3.73(b) is enclosed.		
SIGNATURE of Applicant or Assignee of Record		
Signature		
Name & Title	Mark F. Boshar, V.P. Legal Affairs and Chief Patent Counsel	
Date	Feb. 25, 2008	



STATEMENT UNDER 37 CFR § 3.73(b)

Applicant/Patentee: David Cavalla and Robert William GristwoodApplication No./Patent No.: 10/519,594Filed/Issue Date: December 28, 2004For: 4-(2-Fluorophenyl)-6-Methyl-2(1-Piperazinyl)Thieno[2,3-D] Pyrimidine in the Treatment of Functional Bowel DisorderDynogen Pharmaceuticals, Inc.

(Name of Assignee)

a Corporation

Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)

states that it is:

- A. ☒ the assignee of the entire right, title and interest in the patent application identified above; or
- B. ☐ an assignee together with [] of the entire right, title and interest in the patent application identified above.

The right, title and interest of the above-named assignee in the patent application identified above is established by virtue of:

- A. ☐ An assignment from the inventor(s) of the patent application identified above. The assignment was recorded in the Patent and Trademark Office at Reel [], Frame [], or a copy thereof is attached.

OR

- B. ☒ A chain of title from the inventors of the patent application identified above, to the current assignee as shown below:

1. From: David Cavalla and Robert William Gristwood To: Arachnova LTD.
The document was recorded in the United States Patent and Trademark Office at
Reel 015635, Frames 0169-0170, or a copy thereof is attached.
2. From: Arachnova LTD. To: Arachnova Therapeutics LTD.
The document was recorded in the United States Patent and Trademark Office at
Reel 016517, Frames 0269-0271, or a copy thereof is attached.
3. From: Arachnova Therapeutics Limited To: Dynogen Pharmaceuticals, Inc.
The document was recorded in the United States Patent and Trademark Office at
Reel 020409, Frames 0077-0085, or a copy thereof is attached.

☐ Additional documents in the chain of title are listed on a supplemental sheet.

As required by 37 CFR 3.73(b)(1)(i), the documentary evidence of the chain of title from the original owner to the assignee was, or concurrently is being, submitted for recordation pursuant to 37 CFR 3.11.

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

Signature

Mark F. BosharName: Mark F. BosharTitle: V.P. Legal Affairs and Chief Patent Counsel

Date:

Feb. 25, 2008